Prognia
Drug Database
🇪🇺EU · EMAWithdrawnATC: M05BA06

Bondenza (previously Ibandronic Acid Roche)(ibandronic acid)

Osteoporosis, Postmenopausal

Marketing Authorisation Holder: Roche Registration Ltd.

EMA Authorisation: 23/02/2004

INN: ibandronic acid

Indication

Treatment of osteoporosis in post-menopausal women at increased risk of fracture. A reduction in the risk of vertebral fractures has been demonstrated. Efficacy on femoral-neck fractures has not been established.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Bondenza (previously Ibandronic Acid Roche) — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.